Combination therapy for hemophagocytic lymphohistiocytosis
Part of Blood & lymphatic clinical trials.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with HLH based on at least 5 of the 8 standard criteria (such as fever, enlarged spleen, low blood counts, or high ferritin).
- You must be between 1 and 70 years old.
- You must not have received chemotherapy for HLH before joining this trial.
- If you are pregnant or planning to become pregnant, you must agree to use effective birth control during the study and for at least 12 months after the last dose.
- You must be able to give informed consent (or have a guardian do so if you are a minor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial tests whether a short course of two medicines, dexamethasone (a steroid) and intravenous immunoglobulin (antibodies from donated blood), can help treat a rare condition called hemophagocytic lymphohistiocytosis (HLH) that is triggered by an infection. It may help control the body's overactive immune response and improve organ function.
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has not responded to treatment or has returned. The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study is testing a modified treatment regimen (called DEP) with or without the drug ruxolitinib for patients with HLH, a serious condition where the immune system attacks the body. The goal is to see if this combination is safe and helps control the disease.
Hear when a new Hemophagocytic Lymphohistiocytosis (HLH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.